SolasCure
SolasCure is a Cambridge, UK-based clinical-stage biotechnology company developing Aurase Wound Gel, an investigational biologic hydrogel containing the recombinant enzyme tarumase for enzymatic debridement and accelerated healing of chronic wounds.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SolasCure does
SolasCure Limited is a Cambridge, United Kingdom-based clinical-stage biotechnology company founded in 2017 as a spin-off from German biotech BRAIN Biotech AG. The company is developing a single lead product, Aurase Wound Gel, an investigational biologic hydrogel containing tarumase (provisional International Nonproprietary Name), a recombinant fibrinolytic enzyme cloned from the saliva of medical maggots (Lucilia sericata). The enzyme works through a dual mechanism: it selectively debrides devitalised tissue (fibrin, collagen, elastin) while activating endogenous repair pathways via PAR2 receptors, with pH-dependent activity that self-deactivates as wounds heal. Phase II clinical trials (CLEANVLU2) demonstrated 22x faster debridement and 7x faster healing versus standard of care in chronic venous leg ulcers, and the FDA granted Fast Track Designation in 2025 for calciphylaxis ulcers.
The company is pre-commercial with no product revenue, having invested over USD 30 million to date across approximately GBP 26.3 million in equity financing (Series A GBP 15M in 2021 led by BRAIN Biotech AG and Seneca Partners; Series B GBP 10.9M in 2023 led by Seneca Partners with EVA Pharma, Jonathan Milner, and Wealth Club), plus non-dilutive grants from the European Innovation Council Accelerator (2023) and Innovate UK Biomedical Catalyst (GBP 405K, 2024). The intended revenue model is direct sales of the hydrogel to hospitals, specialist wound care clinics, community care settings, and GP surgeries, with potential licensing and partnership arrangements for commercialization. Pricing has not been disclosed.
SolasCure is advancing commercial readiness through a US Army Institute of Surgical Research collaboration on combat wound care (announced November 2024), selection for Innovate UK's Global Incubator Programme at the Texas Medical Center in Houston to support US market entry (announced June 2024), and a strengthened leadership bench featuring former Smith & Nephew Chief Medical Officer Andy Weymann as Chairman and CEO Lee Harle. The company operates clinical trials across the UK, US, and Hungary and has established an Expanded Access Program contact channel. Key awards include first place in EIT Health Catapult Biotech Category (2022), UK Life Sciences Innovator 2023, and the EIC Accelerator Grant (2023).
SolasCure firmographics
Firmographics- Name
- SolasCure
- Legal name
- Solascure Limited
- Website
- https://solascure.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SolasCure is a Cambridge, UK-based clinical-stage biotechnology company developing Aurase Wound Gel, an investigational biologic hydrogel containing the recombinant enzyme tarumase for enzymatic debridement and accelerated healing of chronic wounds.
- Ownership category
- akta.pro rank
SolasCure industry classification
Industry- Product category
- Wound Care Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)
Keywords
Where SolasCure is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
SolasCure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical/Biologic Product Sales: SolasCure is developing Aurase Wound Gel as an investigational biologic product. Upon regulatory approval, the company will generate revenue through sales of the hydrogel product to healthcare systems, hospitals, wound care clinics, and community care providers. The company has invested over $30 million to date in development.
- Potential Licensing and Partnership Revenue: Following Phase II clinical trial success, the company is seeking partnership engagement and strategic partnerships for product commercialization, which may include licensing arrangements, co-development deals, or distribution partnerships.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
SolasCure product offering
Product offeringCore offering
SolasCure is developing Aurase Wound Gel, an investigational biologic hydrogel containing tarumase — a recombinant fibrinolytic enzyme cloned from medical maggot saliva — for the treatment of chronic wounds. The product performs continuous enzymatic debridement while activating endogenous tissue repair pathways (PAR2 receptors) to accelerate healing of venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers. It is currently in Phase II clinical trials with FDA Fast Track Designation received for calciphylaxis ulcers.
Product overview
SolasCure is a single-product biotechnology company focused on developing Aurase Wound Gel as a mechanism-driven therapeutic for chronic wound healing. The product is a hydrogel formulation containing tarumase (provisional INN), a fibrinolytic enzyme derived from medical maggots. It works through a dual mechanism: continuous enzymatic debridement combined with activation of tissue repair pathways. The product has completed Phase II clinical trials for venous leg ulcers and received FDA Fast Track Designation for calciphylaxis ulcers. Key differentiators include pain-free application, temperature stability for community use, and compatibility with standard wound care workflows.
Differentiator
Problem solved
Functional benefit
Products and services
- Aurase Wound Gel An investigational biologic hydrogel containing tarumase, a recombinant enzyme cloned from medical maggot (Lucilia sericata) saliva, designed for continuous enzymatic debridement and activation of endogenous PAR2 repair pathways. Targeted at chronic wound treatment including venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers, for use in hospitals, specialist wound care clinics, community care settings and home care.
- Expanded Access Program (EAP) Pre-approval access program enabling qualifying patients to receive Aurase Wound Gel prior to full regulatory approval and commercial launch. Contact via [email protected].
Quantifiable outcome
- 22x faster debridement compared to standard of care (65% debridement vs 9% in control after 26 days, p=0.005)
- +3 more outcomes
Companies that use SolasCure
Customer profileSegments3 records
Ideal customer profiles3 records
SolasCure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SolasCure partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major.
- South Leicestershire Medical GroupmajorClinical trial partnership for the CLEANVLU2 Phase II clinical trial being run in association with South Leicestershire Medical Group's community service.
- U.S. Army Institute of Surgical Research (USAISR)majorResearch collaboration to evaluate Aurase Wound Gel for combat wound care. Two non-clinical development projects will assess the enzymatic debridement properties to reduce wound biofilm production and/or bioburden in prolonged field care scenarios, targeting Pseudomonas aeruginosa and MRSA strains.
- Texas Medical Center (TMC)majorPartnership through Innovate UK's Global Incubator Programme. TMC is the largest medical complex globally with over 1,760 life science companies. Programme includes customer discovery, mentorship, investor networking, and engagement with hospital administrators, procurement, and reimbursement professionals.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
SolasCure competitors and assessment
Company assessmentBroad incumbents
- Convatec: Global wound care incumbent with advanced dressings, antimicrobial dressings, and AQUACEL product lines. Comparable as a broad portfolio competitor SolasCure will need to displace or partner with for hospital formulary access in chronic wound care.
- 3M Health Care (Solventum): Spun-off 3M health care business with a major advanced wound care portfolio including Tegaderm and other dressings. Comparable as a global incumbent in chronic wound care procurement channels.
- Mölnlycke Health Care: Swedish wound care specialist with Mepilex, Mepitel, and other advanced dressings. Comparable as a wound-focused incumbent competing in the same chronic wound care procurement channels and clinical settings SolasCure targets.
- Coloplast: Major wound and skin care company with Biatain and other advanced wound dressings. Relevant as a global wound care incumbent SolasCure will compete against in community care, hospital, and home care channels.
- Smith & Nephew: Global medical device leader with a large Advanced Wound Management franchise (including PICO and ACTICOAT). Highly relevant because SolasCure's Chairman Andy Weymann is former Smith & Nephew CMO, and Aurase would compete for formulary slots in the same wound care category Smith & Nephew dominates.
- Integra LifeSciences: Medical device company with a wound care and regenerative tissue portfolio including Integra Dermal Regeneration Template. Comparable as it sells both advanced dressings and biologic/regenerative wound healing products into the same clinical audience.
Emerging players
- Bioventus: Biologics company with wound care and osteoarthritis products including TheraSkin and other skin substitutes for chronic wounds. Comparable as a commercial-stage biologic wound therapy peer overlapping in diabetic foot ulcers and venous leg ulcers.
Others
- BRAIN Biotech AG: SolasCure's founding parent company and current strategic shareholder that originally cloned the tarumase enzyme. Relevant not as a competitor but as a corporate and IP relationship — BRAIN owns the Aurase and SolasCure trademarks and has a continuing board seat.
Direct peers
- Organogenesis: Commercial-stage regenerative medicine company selling skin substitutes and bioactive wound healing products (Apligraf, Dermagraft, PuraPly). Direct comparable as both companies market biologic/regenerative therapies for chronic wounds including venous leg ulcers, addressing the same clinician customer base.
- MiMedx: Sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound healing, including venous leg ulcers and diabetic foot ulcers. Comparable as a regenerative biologic wound therapy commercializing in the same chronic wound indications SolasCure is targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights3 records
Customer concentration
SolasCure social profiles
Digital presenceSolasCure financial estimates
Financial estimateRevenue estimate
Valuation estimate
SolasCure leadership team
Management profileNumber of profiles
Profiles7 records
SolasCure funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SolasCure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SolasCure
What does SolasCure do?
SolasCure is developing Aurase Wound Gel, an investigational biologic hydrogel containing tarumase — a recombinant fibrinolytic enzyme cloned from medical maggot saliva — for the treatment of chronic wounds. The product performs continuous enzymatic debridement while activating endogenous tissue repair pathways (PAR2 receptors) to accelerate healing of venous leg ulcers, diabetic foot ulcers, pressure ulcers, and calciphylaxis ulcers. It is currently in Phase II clinical trials with FDA Fast Track Designation received for calciphylaxis ulcers.
Is SolasCure a public or private company?
SolasCure is a private company. It is classified as venture growth investor backed and is currently operating.
When was SolasCure founded?
SolasCure was founded in 2017. It employs 1 to 10 people.
Where is SolasCure based?
SolasCure is headquartered in Cambridge, United Kingdom, in the Europe region.
How does SolasCure make money?
Two revenue lines are on record. Pharmaceutical/Biologic Product Sales are the primary driver. The others are potential Licensing and Partnership Revenue.
Who are SolasCure's main competitors?
Broad incumbents on record are Convatec, 3M Health Care (Solventum), Mölnlycke Health Care, Coloplast, Smith & Nephew and Integra LifeSciences. Bioventus is listed as an emerging player. BRAIN Biotech AG is listed as an others. Direct peers are Organogenesis and MiMedx.
Does SolasCure have an API?
No public API is recorded for SolasCure.
What industry is SolasCure in?
SolasCure's product category is Wound Care Biologics. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 3841.